Iraj Hosseini

Dr. Iraj Hosseini

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2018 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
IHIraj Hosseini
Iraj Hosseini
AGAnita Gajjala
Anita Gajjala
DYDaniela Bumbaca Yadav
Daniela Bumbaca Yadav
SSSiddharth Sukumaran
Siddharth Sukumaran
SRSaroja Ramanujan
Saroja Ramanujan
KGKapil Gadkar
Kapil Gadkar
Modeling and simulation (M&S) is increasingly used in drug development to characterize pharmacokinetic-pharmacodynamic (PKPD) relationships and support various efforts such as target feasibility assessment, molecule selection, human PK projection, and preclinical and clinical dose and schedule determination. While model development typically require mathematical modeling expertise, model exploration and simulations could in many cases be performed by scientists in various disciplines to support the design, analysis and interpretation of experimental studies. To this end, we have developed a versatile graphical user interface (GUI) application to enable easy use of any model constructed in SimBiology® to execute various common PKPD analyses. The MATLAB®-based GUI application, called gPKPDSim, has a single screen interface and provides functionalities including simulation, data fitting (parameter estimation), population simulation (exploring the impact of parameter variability on the outputs of interest), and non-compartmental PK analysis. Further, gPKPDSim is a user-friendly tool with capabilities including interactive visualization, exporting of results and generation of presentation-ready figures. gPKPDSim was designed primarily for use in preclinical and translational drug development, although broader applications exist. gPKPDSim is a MATLAB®-based open-source application and is publicly available to download from MATLAB® Central™. We illustrate the use and features of gPKPDSim using multiple PKPD models to demonstrate the wide applications of this tool in pharmaceutical sciences. Overall, gPKPDSim provides an integrated, multi-purpose user-friendly GUI application to enable efficient use of PKPD models by scientists from various disciplines, regardless of their modeling expertise.

15 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IHIraj Hosseini
Iraj Hosseini
BFBrett Fleisher
Brett Fleisher
JGJennifer Alice Getz
Jennifer Alice Getz
JDJérémie Decalf
Jérémie Decalf
MKMandy Kwong
Mandy Kwong
SRSaroja Ramanujan
Saroja Ramanujan
FLT3L-Fc is a half-life extended, effectorless Fc-fusion of the native human FLT3-ligand. In cynomolgus monkeys, treatment with FLT3L-Fc leads to a complex pharmacokinetic/pharmacodynamic (PK/PD) relationship, with observed nonlinear PK and expansion of different immune cell types across different dose levels. A minimal physiologically based PK/PD model with expansion-enhanced target-mediated drug disposition (TMDD) was developed to integrate the molecule’s mechanism of action, as well as the complex preclinical and clinical PK/PD data, to support the preclinical-to-clinical translation of FLT3L-Fc. In addition to the preclinical PK data of FLT3L-Fc in cynomolgus monkeys, clinical PK and PD data from other FLT3-agonist molecules (GS-3583 and CDX-301) were used to inform the model and project the expansion profiles of conventional DC1s (cDC1s) and total DCs in peripheral blood. This work constitutes an essential part of our model-informed drug development (MIDD) strategy for clinical development of FLT3L-Fc by projecting PK/PD in healthy volunteers, determining the first-in-human (FIH) dose, and informing the efficacious dose in clinical settings. Model-generated results were incorporated in regulatory filings to support the rationale for the FIH dose selection.

5 July 2025 in EBioMedicine
Verified
Journal Article
Open access
JDJérémie Decalf
Jérémie Decalf
ETEvangeline Toy
Evangeline Toy
DHDongping He
Dongping He
RKRadhika Kenkre
Radhika Kenkre
ABAmy M. Berkley
Amy M. Berkley
CMChristine Moussion
Christine Moussion
Conventional dendritic cells (cDCs), are central to antitumour immunity, but their low prevalence in tumours limits the efficacy of immunotherapies. FLT3L is a key growth factor regulating cDCs development in the bone marrow. It expands cDCs when administered exogenously, favouring antitumour T cell priming and tumour control. Currently, FLT3L pharmacokinetic (PK) and pharmacodynamic (PD) properties require daily dosing for up to 14 days, which may limit its clinical use. In the present study, we developed and characterised a therapeutic modality named FLT3L-Fc NG2LH. We improved human FLT3L PK properties by fusing it with a modified fragment crystallisable (Fc) domain of IgG1. To prevent Fc gamma receptor (FcγR) mediated effector function, we engineered an effectorless Fc format called NG2LH, consisting of the aglycosylation substitution N297G, combined with a graft of the lower hinge region of IgG2 onto an otherwise IgG1 Fc. FLT3L-Fc NG2LH had limited binding to FcγRs and failed to elicit antibody dependent cellular cytotoxicity (ADCC) and cellular phagocytosis (ADCP). PK/PD studies using a mouse effectorless equivalent, mFLT3L-Fc, showed that a single injection of mFLT3L-Fc leads to sustained expansion of cDCs in blood, spleen, and B16F10 tumours. When combined with polyI:C and anti-PD-L1, a single mFLT3L-Fc injection delays the growth of B16F10 tumours and reinvigorates CD8+ T cell immunity. The improved properties of FLT3L-Fc NG2LH are expected to mitigate the practical limitations of FLT3L usage in the clinic, and constitute an asset for future cancer immunotherapy combination regimens leveraging cDC biology in situ. This work was performed at, and funded by Genentech Inc. South San Francisco, CA 94080, USA.

30 September 2025 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
LJLouis R. Joslyn
Louis R. Joslyn
MJMohammad Jafarnejad
Mohammad Jafarnejad
RYRajbharan Yadav
Rajbharan Yadav
PHPatrick G. Holder
Patrick G. Holder
SSShomyseh Sanjabi
Shomyseh Sanjabi
IHIraj Hosseini
Iraj Hosseini
Interleukin-15 (IL-15) is a key pleiotropic cytokine involved in innate and adaptive immunity, promoting proliferation, differentiation, and effector function in lymphocytes. The biologic functions of IL-15 provide a rationale for developing IL-15 agonists as potential cancer treatment, however, IL-15 exhibits a short half-life thereby limiting its therapeutic potential. Recombinant human IL-15 therapies have faced challenges in pharmacokinetics (PK), pharmacodynamics (PD), and safety due to a lack of understanding of the mechanisms leading to expansion of specific immune cell subpopulations following IL-15 therapies. In this work, we develop a quantitative systems pharmacology (QSP) model to capture the dynamics of lymphocyte expansion in response to three engineered IL-15/IL-15Rα therapeutics: a potency engineered Fc-fusion referred to as Efbalropendekin alfa; a heterodimeric, PD-1 targeted cytokine assessed in non-clinical studies (PD1/IL15 TaCk); and an anti-respiratory syncytial virus targeted cytokine that serves as a non-binding isotype control (RSV/IL15 TaCk). The QSP model is able to capture systemic PK and lymphocyte expansion to each of the molecules across different dose levels, thereby offering insights into the complex relationship between PK and PD for these molecules. At molar matched doses, model simulations predict greater drug exposure in the terminal phase of the PK profile following treatment with Efbalropendekin alfa compared to PD1/IL15 TaCk due to the high levels of T cell expansion following administration of PD1/IL15 TaCk. Additionally, our results suggest that while the cell expansion levels in the blood are reflective of dynamics in the tissue, Efbalropendekin alfa and PD1/IL15 TaCk bind to different cell populations in the blood but similar cell populations in the tissue due to the relatively large number of PD1 expressing CD4+ and CD8+ T cells in tissue. Finally, we leverage our QSP modeling framework to generate virtual cohorts with various translational scenarios to make clinical PK/PD predictions in response to PD1/IL15 TaCk treatment. Overall, the systems modeling presented herein offers a novel approach to integrate non-clinical datasets, aid in translation, and support dosing decisions for cytokine-based therapies that activate the immune system and display a dynamic PK/PD relationship.